Urology Today.net

Site updated at Thursday, 12 May 2016

Common Urological Problems


FDA Approves Xtandi for Late-Stage Castration-Resistant Prostate Cancer

The U.S. Food and Drug Administration today approved Xtandi (enzalutamide) to treat men with late-stage (metastatic) castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone.

Approved for prostate cancer patients previously treated with docetaxel, another anti-cancer treatment, Xtandi was reviewed under the FDA’s priority review program.… FDA Approves Xtandi for Late-Stage Castration-Resistant Prostate Cancer   

fluid retention1 - prostate cancer etiology1 - bladder control4 - catheter-associated urinary tract infection1 - higher blood pressure1 - xanthogranulomatous pyelonephritis1 - prostate cancer screening7 - hyperpnea1 - robot-assisted surgery for prostate cancer1 - health benefits1 - biomarker1 - psa velocity screening1 - anxiety1 - journal of the american society of nephrology4 - hormone erythropoietin1 - pyelolithotomy1 - internal and external genitalia1 - risk of infection2 - mood disorders1 - busm1 - kidney blood pressure1 - aminoaciduria1 - acute kidney injury8 - incontinence10 - noncalcium calculi1 - robotic-surgery1 - psa tests1 - aus1 - abiraterone2 - persistent incontinence1 -